Introduction
Rifampicin was first used for treating leprosy after it was found to inhibit the multiplication of Mycobacterium leprae in mice and after our pilot clinical studies had indicated that it was initially more effective than standard dapsone treatment. We also found that rifampicin was unique among anti-leprosy drugs in possessing rapid bactericidal activity.' These observations, substantiated by others,2-4 encouraged further investigations. From 1968 to 1977 over 100 patients with lepromatous leprosy have been treated with rifampicin at the Leprosy Research Unit, Malaysia. We report here the results of a series of wide-ranging short-and long-term clinical trials, including bacteriological surveillance by mouse footpad inoculation.
Patients and methods

BACTERIOLOGICAL STUDIES
Because M leprae cannot be cultured in vitro, bacterial growth was assessed in the footpads of strain CBA mice. The tests were performed at the National Institute for Medical Research, London. Both hind footpads of normal mice were inoculated with 104 acid-fast bacilli (AFB), and scored positive if 5 x 104 or more bacilli were recovered by 12 months.5 Six mice were used for each test. In many assessments similar groups of immunologically deficient CBA mice (T/R mice, who had undergone thymectomy in adolescence and subsequent irradiation by five exposures of 200 rads every two weeks) were also included. Unlike normal mice, the T/R mice supported growth from inocula > 104 AFB/footpad and they also had a possible overall increased susceptibility to M leprae.' The T/R mice were routinely inoculated with 105 AFB in both hind footpads and scored positive (confirming the presence of viable AFB) if 5 x 105 or more AFB were recovered by 12 months. When yields of AFB from biopsy specimens were low or even uncountable, inocula necessarily included fewer than 104 or 105 AFB. In such experiments a fivefold increase in yield or a yield of 5 x 104 (lower limit of assessment) resulting from an uncountable inoculum was scored positive.
Footpad tests were used to determine the sensitivity of M leprae to rifampicin and to determine the viability of M leprae.
Sensitivity to rifampicin-Ten strains of M leprae, four from untreated patients and six from patients with sulphone-resistant lepromatous leprosy, were tested. Four groups of six normal mice were infected with each strain; three groups were fed with rifampicin incorporated in the diet at concentrations of 0-01 %, 0 005 %, and 0-0025 %, and the fourth was left untreated. The minimum effective dose of rifampicin was calculated on a body-weight basis from the lowest concentration of drug in the diet that completely suppressed the growth of AFB.
Viability of M leprae-Tissue specimens were obtained by biopsy from patients before and during treatment; they were homogenised and bacillary suspensions were prepared5 for footpad inoculations of normal or T/R mice, or both. were admitted to this open-ended trial; so far they have been followed up for three to eight and a half years. Sixty-five had leprosy that had proved resistant to dapsone,9 including five who were also resistant to thiambutosine; two additional patients suffered from sulphone allergy and had developed thiambutosine resistance. The first four patients who were admitted, and all those who were resistant to thiambutosine, were treated with rifampicin 600 mg/day. The remainder received combined treatment with rifampicin, usually 600 mg/day, though seven received intermittent (weekly) rifampicin, and thiambutosine 1 g twice daily by mouth or 1 g weekly by injection.
Regular independent clinical, histological, and bacteriological assessments were performed; episodes of erythema nodosum leprosum (ENL) were noted; and sera from patients on intermittent treatment were monitored for rifampicin-dependent antibodies.1' Thirty-three patients were specially studied for the presence of persisting, viable M leprae in biopsy specimens taken from skin, striated muscle, nerve, and, in men, dartos after six months and one, two, two and a half,ll or five years of continuous treatment.
Results
MINIMUM EFFECTIVE DOSE OF RIFAMPICIN
In mice all 10 strains of M leprae, whether sensitive or resistant to dapsone, were inhibited by doses of rifampicin of 20 mg/kg body weight/day and 10 mg/kg/day; three strains were also inhibited by 5 mg/kg/day. The minimum effective dose of rifampicin in the mouse is therefore about 8 mg/kg/day.
PILOT TRIAL All patients showed a rapid clinical response to rifampicin. The MI from skin smears fell appreciably after two weeks' treatment in almost all patients, and in all it approached zero after only four to six weeks.
CONTROLLED CLINICAL TRIALS
The first trial confirmed that the initial clinical response and rate of fall in the smear MI occurred much more rapidly with rifampicin than with dapsone. Blockage of the nose was relieved, superficial scabbing and ulceration of lepromatous papules healed, and lesions became less erythematous and papules less tense and fleshy within 10 to 21 days. The comparable response on dapsone took six to 12 weeks. Mouse footpad testing (table I) showed that after only three weeks very few leprosy bacilli from rifampicin-treated patients could multiply, whereas no loss of viability could be detected at six weeks in patients on dapsone.
Multiple-site biopsies taken at three months in the second trial showed significant loss of bacterial viability in both treatment groups, although the loss was much greater on combined treatment than on dapsone alone. At six months 19 out of 199 footpads inoculated with M leprae prepared from the tissues of dapsone-treated patients showed bacterial multiplication compared with only two out of 152 footpads from the combined treatment group (table II) . There was no evidence that after this length of treatment any one of the four tissue sites favoured the persistence of M leprae.
Although we got the impression that ENL developed on average earlier in patients treated with rifampicin than in those receiving dapsone alone, we studied too few patients to attain significant results. The overall severity of ENL experienced by individual patients seemed to be unrelated to the treatment group to which they belonged. There was no evidence of a sudden, severe onset of ENL, comparable to a Jarisch-Herxheimer reaction in patients with syphilis treated with penicillin.
LONG-TERM TRIAL
All the patients who were resistant to dapsone showed the same rapid initial clinical improvement and fall in the MI on rifampicin as the untreated patients. After the first three or four months of treatment, however, the subsequent rate of progress was much the same as that under treatment with clofazimine (Lamprene, B 663), including the rate of removal of dead leprosy bacilli as assessed by the BI of skin smears. 1 12 Persisting viable M leprae were detected in 26 of the 33 patients specially studied by biopsies of multiple tissue sites (table III) ; all four sites were implicated. The proportion of positive sites was no less after two years than after six months or one year of treatment. More--over, even after five years of rifampicin treatment seven out of 12 patients had at least one site (table IV) that yielded viable M leprae; they included seven of the eight patients who had biopsy specimens taken from at least three sites.
Three strains of M leprae isolated from patients treated for six months were shown to be fully sensitive to rifampicin. analogy with the chemotherapy of tuberculosis,l4 alternative, preferably bactericidal, drugs are required for an intensive initial phase of combined treatment.15 This would be used principally to prevent the later emergence of dapsone resistance but also in an attempt to hasten the elimination of persisters and thereby to shorten the often lifelong period of treatment required in lepromatous leprosy.
Rifampicin has proved promising since its introduction. Clinical improvement can be detected within two weeks, although in the long term there is no evidence that rifampicin speeds the removal of dead leprosy bacilli.1' 12 The drug is more rapidly bactericidal than any established anti-leprosy drug; this has been shown both indirectly by the rate of fall of the MI and directly by mouse footpad inoculation of suspensions obtained from either serial skin biopsiesl 3 4 or serial "nose-blows" (R J W Rees and A C McDougall, unpublished observations, 1973). Patients with lepromatous leprosy ceased to present a significant public health risk within a few days of starting rifampicin, and provided that the precautions recommended from experience in the treatment of tuberculosis'6 17 were observed, the toxic effects of rifampicin were negligible. ENL was no more severe than with dapsone.
Our pilot studies' and the extensive studies of Shepard et al,3 4 also suggested that rifampicin rapidly reduced persisters to undetectable levels. But, by using a more sensitive technique, giving inocula of up to 105 bacteria to T/R mice, we have been able to detect persisters five years after the start of treatment with rifampicin alone or combined with the bacteriostatic drug thiambutosine."1 It therefore seems unlikely that rifampicin by itself could significantly shorten the total length of treatment in lepromatous leprosy. Furthermore, the first case of leprosy resistant to rifampicin has already been reported'8 in a patient receiving treatment with rifampicin.
Combined treatment needs further investigation. In full dosage dapsone is slowly bactericidal for M leprae.'9 In our studies persisters were barely detectable in dapsone-sensitive patients treated for six months with rifampicin 600 mg/day plus dapsone 100 mg/day and were significantly less common than in patients treated with dapsone alone. It is also reasonable to assume that an initial course of combined treatment would largely prevent the later emergence of dapsone resistance (provided that dapsone continued to be taken regularly), although it may require 30 years to prove this. The other bactericidal anti-leprosy drugs, which can be combined with rifampicin in treating patients resistant to dapsone, are clofazimine and ethionamide or prothionamide.'0 It is possible, again by analogy with tuberculosis, that an initial intensive phase of treatment with three or four drugs might be even more effective than dual treatment. Freerksen2' has advocated the widespread and prolonged use of combinations of dapsone, rifampicin, prothionamide, and isoniazid (although the latter drug has little effect on leprosy bacilli), but his trials did not include adequate bacteriological investigations. He therefore, assessed his regimen by stopping all treatment after various periods and monitoring the subsequent relapse rate22 -an effective "test of cure," although demanding for both the doctor and his patients.
Such a test of cure needs to be applied very cautiously, for there is no anti-leprosy drug comparable with pyrazinamide, which can act on semi-dormant tubercle bacilli.23 Moreover, patients with lepromatous leprosy are incapable of producing effective cell-mediated immunity against M leprae, even after many years of treatment. Therefore multiple drug combinations may be incapable of eliminating all persisting M leprae. Should this prove to be so then the final cure of lepromatous leprosy, if it is to be achieved in years rather than decades, may well depend not on chemotherapy alone, but on a combination of chemotherapy and immunotherapy. the main physiological inhibitor of thrombin is antithrombin III (ATIII).3 The physiological importance of ATIII is emphasised by the fact that it inhibits other activated coagulation factors, including factors IXa, Xa, XIa, and XIIa.-7 These inhibitory actions of ATIII are accelerated in the. presence of low heparin concentrations and ATIII is probably identical with the agent formerly known as plasma heparin cofactor. [8] [9] [10] A predisposition to venous thrombosis, such as is acquired during oestrogen treatment and surgery, has been associated with reduced ATIII concentrations.8 11-13 A clearer. association of venous thrombosis with reduced concentrations of this coagulation inhibitor occurs in the rare hereditary deficiency of ATIII.14 We describe here a large family in which major thromboembolic disease was associated with ATIII deficiency. To our knowledge. this represents the first such family studied in the British Isles. Normal controls-These were medical and laboratory staff and students free from intercurrent and chronic disease, none of whom had ever sustained an episode of thromboembolism or superficial phlebitis.
Patients and methods
Functional A TIII assay-The progressive antithrombin assay, after heat defibrination of plasma, was used.15
